The rise of Sildenafil initially drove a surge for the drug industry, however recent changes present a complicated scenario for investors. Off-patent alternatives are eating into revenue, and ongoing legal battles add https://sabrinaxoza084827.tokka-blog.com/41607717/the-blue-pill-and-the-pharmaceutical-industry-a-risky-bet